dc.contributor.author | Gente Lidholm, Anette | |
dc.date.accessioned | 2021-11-09T14:55:19Z | |
dc.date.available | 2021-11-09T14:55:19Z | |
dc.date.issued | 2021-11-09 | |
dc.identifier.isbn | 978-91-8009-494-8 (PRINT) | |
dc.identifier.isbn | 978-91-8009-495-5 (PDF) | |
dc.identifier.uri | http://hdl.handle.net/2077/69329 | |
dc.description.abstract | Background: Aluminium contact dermatitis is rare even though aluminium is
frequently used in antiperspirants and sunscreens. Sensitisation to aluminium
is mostly a side effect of aluminium-adsorbed vaccines. These can also induce
long-lasting intensely itching subcutaneous nodules (granulomas) at the injection
site.
During clinical trials on an acellular aluminium-adsorbed pertussis vaccine in the
1990s in Gothenburg, Sweden, persistent itching nodules were -unexpectedly- reported in 745 of ~ 76 000 vaccinated. Contact dermatitis to aluminium was
verified by patch test in 377 children with itching nodules.
Aim: This thesis aims to study the long-term clinical prognosis of itching subcutaneous nodules and aluminium allergy in children who received an aluminium-adsorbed pertussis vaccine in a clinical trial.
Patients and Methods: All 745 vaccinated children with itching nodules in the
pertussis vaccine trial were enrolled in a long-term follow-up study (>20 years).
Results: The median duration of itching was 6.6 years. During the follow-up
time 637/745 (86%) of the participants experienced full symptom recovery. The
remaining were markedly improved. In 186 of 241 (77%) children who were
tested twice, aluminium hypersensitisation was no longer detectable. A negative
patch test was significantly correlated with loss of itching. 3-7% of the participants who received other aluminium-adsorbed vaccines later in life reported mild
and transient itching at the new injection site. The optimal compound to establish aluminium hypersensitivity could not be determined.
Conclusion and recommendations: Vaccine-induced subcutaneous itching nodules associated with aluminium allergy in infants and children can cause great
suffering and have a protracted course. However, long-term prospective studies5
show that both clinical symptoms and delayed hypersensitivity for aluminium
disappear over time. Further vaccination with aluminium-adsorbed vaccines is
safe in older children given that the original nodule has vanished and the itching
will have resolved or nearly resolved. | sv |
dc.language.iso | eng | sv |
dc.relation.haspart | I. Gente Lidholm A, Bergfors E, Inerot A, Blomgren U, Gillstedt M, Trollfors B.
Unexpected loss of contact allergy to aluminium induced by vaccine. Contact dermatitis.
2013;68(5):286-92. ::doi::10.1111/cod.12053 | sv |
dc.relation.haspart | II. Gente Lidholm A, Inerot A, Gillstedt M, Bergfors E, Trollfors B. Comparison of
reactivity to a metallic disc and 2% aluminium salt in 366 children, and reproducibility
over time for 241 young adults with childhood vaccine-related aluminium contact allergy.
Contact Dermatitis 2018; Jul;79(1):26-30. ::doi::10.1111/cod.12977 | sv |
dc.relation.haspart | III. Gente Lidholm A, Inerot A, Gillstedt M, Bergfors E, Trollfors B. Long-term clinical
course and prognosis of vaccine-related persistent itching nodules. Manuscript submitted for publication. | sv |
dc.relation.haspart | IV. Gente Lidholm A, Inerot A, Gillstedt M, Bergfors E, Trollfors B. Long-term prognosis of
vaccine-induced contact allergy to aluminium - third patch-test and different test
preparations. In manuscript. | sv |
dc.subject | Childhood vaccine | sv |
dc.subject | Adverse event | sv |
dc.subject | Aluminium | sv |
dc.subject | Aluminium allergy | sv |
dc.subject | Itching nodules | sv |
dc.subject | Subcutaneous granulomas | sv |
dc.subject | Patch test | sv |
dc.subject | Tolerance | sv |
dc.title | Vaccine-induced aluminium allergy and long-lasting subcutaneous itching nodules | sv |
dc.type | text | eng |
dc.type.svep | Doctoral thesis | eng |
dc.gup.mail | anette.gente.lidholm@gu.se | sv |
dc.type.degree | Doctor of Philosophy (Medicine) | sv |
dc.gup.origin | University of Gothenburg. Sahlgrenska Academy | sv |
dc.gup.department | Institute of Clinical Sciences. Department of Dermatology and Venereology | sv |
dc.gup.defenceplace | Torsdagen den 2 december 2021, kl 9.00, Hörsal Arvid Carlsson, Academicum, Medicinaregatan 3, Göteborg | sv |
dc.gup.defencedate | 2021-12-02 | |
dc.gup.dissdb-fakultet | SA | |